organization · Reporting owner
Versant V Luxco S.a r.l.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aprea Therapeutics, Inc.
Report date April 09, 2020 · Filed May 20, 2020
Jointly reported with Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Venture Capital V (Canada), LP, Versant Ventures V, LLC, Versant Ventures V (Canada), L.P.
Section 16 reporting ended · disclosed 2020-05-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-04-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-04-09 · Other · Disposed 2,519,323 · Balance 0 F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant V Luxco S.a.r.l. ("Luxco") to its shareholders without consideration. F2: These Shares are directly held by Versant VI Luxco S.a.r.l. ("Luxco"). F3: Luxco is majority owned by Versant Venture Capital V, L.P.("VVC V") and minority owned by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), Versant Affiliates Fund V, L.P. ("VAF V" and together with VVC V and VOA, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V, LLC ("VV V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which is the general partner of VVC CAN. |
| Common StockSEC Table I · non-derivative | Direct | 2,210,937 |
Reported balance
After 2020-04-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-04-09 · Other · Acquired 2,210,937 · Balance 2,210,937 F4: Represents a change in the form of ownership of VVC V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F5: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 66,506 |
Reported balance
After 2020-04-09 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-04-09 · Other · Acquired 66,506 · Balance 66,506 F6: Represents a change in the form of ownership of VAF V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F7: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 73,617 |
Reported balance
After 2020-04-09 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-04-09 · Other · Acquired 73,617 · Balance 73,617 F8: Represents a change in the form of ownership of VOA by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F9: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | Direct | 168,263 |
Reported balance
After 2020-04-09 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2020-04-09 · Other · Acquired 168,263 · Balance 168,263 F10: Represents a change in the form of ownership of VVC CAN by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F11: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,437,132 |
Reported balance
After 2020-05-18 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2020-05-18 · Other · Disposed 773,805 · Balance 1,437,132 F12: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC V without consideration to its partners. F5: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 43,231 |
Reported balance
After 2020-05-18 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2020-05-18 · Other · Disposed 23,275 · Balance 43,231 F13: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VAF V without consideration to its partners. F7: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 47,823 |
Reported balance
After 2020-05-18 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2020-05-18 · Other · Disposed 25,794 · Balance 47,823 F14: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VOA without consideration to its partners. F9: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | Direct | 109,374 |
Reported balance
After 2020-05-18 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2020-05-18 · Other · Disposed 58,889 · Balance 109,374 F15: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC CAN without consideration to its partners. F11: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | Direct | 16,428 |
Reported balance
After 2020-05-18 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2020-05-18 · Other · Acquired 16,428 · Balance 16,428 F16: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA. F17: The shares are held by VV V. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-18 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2020-05-18 · Other · Disposed 16,428 · Balance 0 F18: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members. F17: The shares are held by VV V. |
| Common StockSEC Table I · non-derivative | Direct | 1,178 |
Reported balance
After 2020-05-18 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2020-05-18 · Other · Acquired 1,178 · Balance 1,178 F19: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN. F20: The shares are held by VV V CAN. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-18 transaction · row 13
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 13 · 2020-05-18 · Other · Disposed 1,178 · Balance 0 F21: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners. F20: The shares are held by VV V CAN. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant V Luxco S.a.r.l. ("Luxco") to its shareholders without consideration.
F2: These Shares are directly held by Versant VI Luxco S.a.r.l. ("Luxco").
F3: Luxco is majority owned by Versant Venture Capital V, L.P.("VVC V") and minority owned by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), Versant Affiliates Fund V, L.P. ("VAF V" and together with VVC V and VOA, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V, LLC ("VV V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which is the general partner of VVC CAN.
F4: Represents a change in the form of ownership of VVC V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.
F5: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.
F6: Represents a change in the form of ownership of VAF V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.
F7: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein.
F8: Represents a change in the form of ownership of VOA by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.
F9: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein.
F10: Represents a change in the form of ownership of VVC CAN by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco.
F11: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein.
F12: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC V without consideration to its partners.
F13: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VAF V without consideration to its partners.
F14: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VOA without consideration to its partners.
F15: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC CAN without consideration to its partners.
F16: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA.
F17: The shares are held by VV V.
F18: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members.
F19: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN.
F20: The shares are held by VV V CAN.
F21: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 1,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 13 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F21 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners. F20 · ownership.direct: The shares are held by VV V CAN. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 1,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 12 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,178 F19 · kind: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN. F20 · ownership.direct: The shares are held by VV V CAN. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 16,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 11 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F18 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members. F17 · ownership.direct: The shares are held by VV V. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 16,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 10 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 F16 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA. F17 · ownership.direct: The shares are held by VV V. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 58,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 9 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,374 F15 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC CAN without consideration to its partners. F11 · ownership.direct: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 25,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 8 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,823 F14 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VOA without consideration to its partners. F9 · ownership.direct: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 23,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 7 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,231 F13 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VAF V without consideration to its partners. F7 · ownership.direct: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 773,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 6 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,437,132 F12 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VVC V without consideration to its partners. F5 · ownership.direct: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. Read SEC document |
| April 09, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 168,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 5 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,263 F10 · kind: Represents a change in the form of ownership of VVC CAN by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F11 · ownership.direct: These securities are held of record by VVC CAN. VV V CAN GP is the sole general partner of "VV V CAN and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. VV V CAN disclaims beneficial ownership of the shares held by VVC CAN, except to the extent of its pecuniary interests therein. Read SEC document |
| April 09, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 73,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 4 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,617 F8 · kind: Represents a change in the form of ownership of VOA by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F9 · ownership.direct: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of such shares except to the extent of its pecuniary interests therein. Read SEC document |
| April 09, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 66,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 3 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,506 F6 · kind: Represents a change in the form of ownership of VAF V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F7 · ownership.direct: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial owners of such shares except to the extent of its pecuniary interest therein. Read SEC document |
| April 09, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 2,210,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 2 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,210,937 F4 · kind: Represents a change in the form of ownership of VVC V by virtue of receipt of shares in the pro-rata in-kind distribution of Common Stock by Luxco. F5 · ownership.direct: These securities are held of record by VVC V. VV is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VVC V disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. Read SEC document |
| April 09, 2020 Filed May 20, 2020 21:59 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | OtherCommon Stock | 2,519,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064448 · a4.xml · nonDerivative · entry 1 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant V Luxco S.a.r.l. ("Luxco") to its shareholders without consideration. F2 · ownership.direct: These Shares are directly held by Versant VI Luxco S.a.r.l. ("Luxco"). F3 · ownership.direct: Luxco is majority owned by Versant Venture Capital V, L.P.("VVC V") and minority owned by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"), Versant Affiliates Fund V, L.P. ("VAF V" and together with VVC V and VOA, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V, LLC ("VV V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the general partner of Versant Ventures V (Canada), L.P. ("VV V CAN"), which is the general partner of VVC CAN. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 19:39 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | ConversionSeries C Convertible Preferred Stock · Derivative | 512,995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-19-018090 · form4.xml · derivative · entry 5 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 512,995 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l. F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 19:39 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,993,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-19-018090 · form4.xml · derivative · entry 4 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,993,658 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l. F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 19:39 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 333,333 | $15.00 | $4,999,995.00 |
DisclosureSEC source: 0001140361-19-018090 · form4.xml · nonDerivative · entry 3 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 333,333 F4 · ownership.direct: These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. F4 · ownership.nature: These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5 · ownership.nature: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 19:39 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | ConversionCommon Stock | 512,995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-19-018090 · form4.xml · nonDerivative · entry 2 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,519,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l. F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 19:39 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | ConversionCommon Stock | 1,993,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-19-018090 · form4.xml · nonDerivative · entry 1 Versant V Luxco S.a r.l. · CIK 0001786141 · 10% owner Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,006,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l. F3 · ownership.direct: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5 · ownership.direct: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.